![[Translate to Deutsch:]](/fileadmin/HIPS/__processed__/c/5/csm_HIPS_50503_431fe075f3.jpg "[Translate to Deutsch:]")
Dr. Walid A. M. Elgaher
Über
Dr. Walid A. M. Elgaher studierte Pharmazie an der Universität Assiut (Ägypten). Er erhielt ein Stipendium des Deutschen Akademischen Austauschdienstes (DAAD) für seine Promotion in Deutschland. 2016 promovierte er in Medizinischer Chemie unter Betreuung von Prof. Rolf W. Hartmann an der Universität des Saarlandes. Anschließend kehrte er nach Ägypten zurück und wurde zum Dozenten für Pharmazeutische Organische Chemie an der Fakultät für Pharmazie der Universität Assiut ernannt. 2017 schloss er sich der Gruppe von Prof. Anna K. H. Hirsch als Postdoktorand am HIPS an, und ist seit 2024 Habilitand an der Universität des Saarlandes. Schwerpunkte seiner Arbeiten sind die Anwendung moderner Arzneimitteldesignansätze zur Behandlung ungenutzter therapeutischer Targets sowie der Einsatz biophysikalischer und computergestützter Techniken zur Arzneimittelentdeckung und -optimierung.
2025
Discovery of a novel, selective CK2 inhibitor class with an unusual basic scaffold
Khalifa H, ElHady A, Liu T, Elgaher W, Filhol-Cochet O, Cochet C, Abadi A, Hamed M, Abdel-Halim M, Engel M (2025)
European journal of medicinal chemistry 282DOI: 10.1016/j.ejmech.2024.117048
2024
Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic A, Kress A, Carter-Timofte M, Holm E, van der Horst D, …, Alain T, Olagnier D (2024)
Nat Commun 15 (1)DOI: 10.1038/s41467-024-55044-w
Novel and Extremely Sensitive NiAl2O4-NiO Nanostructures on an ITO Sensing Electrode for Enhanced Detection of Ascorbic Acid
Hammami A, Bardaoui A, Eissa S, Elgaher W, Chtourou R, Messaoud O (2024)
Molecules (Basel, Switzerland) 29 (12)DOI: 10.3390/molecules29122837
Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic A, Kress A, Carter-Timofte M, Holm E, van der Horst D, …, Alain T, Olagnier D (2024)
Nat Commun 15 (1)DOI: 10.1038/s41467-024-48422-x
Clean Synthetic Strategies to Biologically Active Molecules from Lignin: A Green Path to Drug Discovery**
Afanasenko A, Wu X, Santi A, Elgaher W, Kany A, Shafiei R, Schulze M, Schulz T, Haupenthal J, Hirsch A, Barta K (2024)
Angewandte Chemie (Weinheim an der Bergstrasse, Germany) 136 (4)DOI: 10.1002/ange.202308131
Expression and characterization of pantothenate energy-coupling factor transporters as an anti-infective drug target
Shams A, Bousis S, Diamanti E, Elgaher W, Zeimetz L, Haupenthal J, slotboom d, Hirsch A (2024)
Protein Sci. 33 (11)DOI: 10.1002/pro.5195
Dual inhibitors of Pseudomonas aeruginosa virulence factors LecA and LasB
Metelkina O, Konstantinovic J, Klein A, Shafiei R, Fares M, Alhayek A, Yahiaoui S, Elgaher W, Haupenthal J, Titz* A, Hirsch* A (2024)
Chem. Sci. 15DOI: 10.1039/D4SC02703E
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
Sake S, Zhang X, Rajak M, Urbanek-Quaing M, Carpentier A, Gunesch A, Grethe C, Matthaei A, Rückert J, Galloux M, …, Haid* S, Pietschmann* T (2024)
Nat. Commun. 15 (1)DOI: 10.1038/s41467-024-45241-y
2023
Korrektur der absoluten Konfiguration von Chelocardin und Amidochelocardin
Sikandar A, Popoff A, Jumde R, Mándi A, Kaur A, Elgaher W, Rosenberger L, Hüttel S, Jansen R, Hunter M, …, Kurtán T, Müller R (2023)
Angewandte Chemie (Weinheim an der Bergstrasse, Germany) 135 (40)DOI: 10.1002/ange.202306437
Clean Synthetic Strategies to Biologically Active Molecules from Lignin: A Green Path to Drug Discovery
Afanasenko A, Wu X, Santi A, Elgaher W, Kany A, Shafiei R, Schulze M, Schulz T, Haupenthal J, Hirsch A, Barta K (2023)
Angew. Chem. Int. Ed.DOI: 10.1002/anie.202308131
NRF2 activators inhibit influenza A virus replication by interfering with nucleo-cytoplasmic export of viral RNPs in an NRF2-independent manner
Waqas F, Shehata M, Elgaher W, Lacour A, Kurmasheva N, Begnini F, Kiib A, Dahlmann J, Chen C, Pavlou A, …, Pleschka S, Pessler F (2023)
PLOS Pathogens 19 (7)DOI: 10.1371/journal.ppat.1011506
Revision of the Absolute Configurations of Chelocardin and Amidochelocardin
Sikandar A, Popoff A, Jumde R, Mándi A, Kaur A, Elgaher W, Rosenberger L, Hüttel S, Jansen R, Hunter M, …, Kurtán T, Müller R (2023)
Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202306437
2022
Screening of Natural Products and Small Molecules Uncovers Novel Coronavirus 1a/1b Frameshifting Inhibitors with Antiviral Properties
Kibe A, Elgaher W, Rand U, Zimmer M, Kany A, Hermann J, Müller R, Cicin-Sain L, Hirsch A, Caliskan N (2022)
SSRN JournalDOI: 10.2139/ssrn.4157446
Design, Synthesis, Antimicrobial Activity, and Molecular Docking of Some New Diclofenac Derivatives
Tolba M, Hamed M, Sayed M, Kamal El-Dean A, Abdel-Mohsen S, Ibrahim O, Elgaher W, Hirsch A, Saddik A (2022)
Polycyclic Aromatic Compounds: 1-16DOI: 10.1080/10406638.2022.2102661
Citraconate inhibits ACOD1 (IRG1) catalysis, reduces interferon responses and oxidative stress, and modulates inflammation and cell metabolism
Chen F, Elgaher W, Winterhoff M, Büssow K, Waqas F, Graner E, Pires-Afonso Y, Casares Perez L, La Vega L, Sahini N, …, Hirsch A, Pessler F (2022)
Nature metabolism 4 (5): 534-546DOI: 10.1038/s42255-022-00577-x
2021
Citatronic Acid and Derivates thereof for use as a medicament
Pessler F., Chen F., Winterhoff M., Büssow K., Blankenfeldt W., Hirsch A. K. H., Elgaher W (2021)
Patent (WO2022223778, 2022)
Identification of N,N-arylalkyl-picolinamide derivatives targeting the RNA-binding protein HuR, by combining biophysical fragment-screening and molecular hybridization
Della Volpe S, Linciano P, Listro R, Tumminelli E, Amadio M, Bonomo I, Elgaher W, Adam S, Hirsch A, Boeckler F, …, Rossi D, Collina S (2021)
Bioorganic chemistry 116DOI: 10.1016/j.bioorg.2021.105305
Hit-optimization using target-directed dynamic combinatorial chemistry: Development of inhibitors of the anti-infective target 1-deoxy-D-xylulose-5-phosphate synthase
Jumde R, Guadigni M, Gierse R, Alhayek A, Di Zhu, Hamid Z, Johannsen S, Elgaher W, Neusens P, Nehls C, …, Reiling N, Hirsch A (2021)
Chemical ScienceDOI: 10.1039/D1SC00330E
2020
A hydrogel-based in vitro assay for the fast prediction of antibiotic accumulation in Gram-negative bacteria
Richter R, Kamal M, García-Rivera M, Kaspar J, Junk M, Elgaher W, Srikakulam S, Gress A, Beckmann A, Grißmer A, …, Schneider-Daum N, Lehr C (2020)
Materials today. Bio 8DOI: 10.1016/j.mtbio.2020.100084
Semisynthesis and biological evaluation of amidochelocardin derivatives as broad-spectrum antibiotics
Grandclaudon C, Birudukota N, Elgaher W, Jumde R, Yahiaoui S, Arisetti N, Hennessen F, Hüttel S, Stadler M, Herrmann J, …, Hirsch A, Brönstrup M (2020)
European journal of medicinal chemistry 188DOI: 10.1016/j.ejmech.2019.112005
Discovery of Small-Molecule Stabilizers of 14-3-3 Protein-Protein Interactions via Dynamic Combinatorial Chemistry
Hartman A, Elgaher W, Hertrich N, Andrei S, Ottmann C, Hirsch A (2020)
ACS medicinal chemistry letters 11 (5): 1041-1046DOI: 10.1021/acsmedchemlett.9b00541
Cystobactamid 507: Concise Synthesis, Mode of Action, and Optimization toward More Potent Antibiotics
Elgaher W, Hamed M, Baumann S, Herrmann J, Siebenbürger L, Krull J, Cirnski K, Kirschning A, Brönstrup M, Müller R, Hartmann R (2020)
Chem. Eur. J. 26 (32): 7219-7225DOI: 10.1002/chem.202000117
Evaluation of Bacterial RNA Polymerase Inhibitors in a Staphylococcus aureus-Based Wound Infection Model in SKH1 Mice
Haupenthal J, Kautz Y, Elgaher W, Pätzold L, Röhrig T, Laschke M, Tschernig T, Hirsch A, Molodtsov V, Murakami K, Hartmann R, Bischoff M (2020)
ACS infectious diseases 6 (10): 2573-2581DOI: 10.1021/acsinfecdis.0c00034
Protein‐Templated Hit Identification via an Ugi Four‐Component Reaction
Mancini F, Unver M, Elgaher W, Jumde V, Alhayek A, Lukat P, Herrmann J, Witte M, Köck M, Blankenfeldt W, Müller R, Hirsch A (2020)
Chem. Eur. J.DOI: 10.1002/chem.202002250
Potential Dental Biofilm Inhibitors: Dynamic Combinatorial Chemistry Affords Sugar-Based Molecules that Target Bacterial Glucosyltransferase
Hartman A, Jumde V, Elgaher W, Te Poele E, Dijkhuizen L, Hirsch A (2020)
ChemMedChemDOI: 10.1002/cmdc.202000222
Synthetic studies of cystobactamids as antibiotics and bacterial imaging carriers lead to compounds with high in vivo efficacy
Testolin G, Cirnski K, Rox K, Prochnow H, Fetz V, Grandclaudon C, Mollner T, Baiyoumy A, Ritter A, Leitner C, …, Müller R, Brönstrup M (2020)
Chemical Science 11 (5): 1316-1334DOI: 10.1039/C9SC04769G
Discovery of Novel Latency-Associated Nuclear Antigen Inhibitors as Antiviral Agents Against Kaposi's Sarcoma-Associated Herpesvirus
Kirsch P, Jakob V, Elgaher W, Walt C, Oberhausen K, Schulz T, Empting M (2020)
ACS chemical biology 15 (2): 388-395DOI: 10.1021/acschembio.9b00845
2019
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis
Lababidi N, Ofosu Kissi E, Elgaher W, Sigal V, Haupenthal J, Schwarz B, Hirsch A, Rades T, Schneider M (2019)
Journal of Controlled Release 314: 62-71DOI: 10.1016/j.jconrel.2019.10.038
Reversible immobilization of a protein to a gold surface through multiple host-guest interactions
Schwarz D, Elgaher W, Hollemeyer K, Hirsch A, Wenz G (2019)
J. Mater. Chem. B 7 (40): 6148-6155DOI: 10.1039/c9tb00560a
2018
In Vitro Model of the Gram-Negative Bacterial Cell Envelope for Investigation of Anti-Infective Permeation Kinetics
Graef F, Richter R, Fetz V, Murgia X, Rossi C, Schneider-Daum N, Allegretta G, Elgaher W, Haupenthal J, Empting M, …, Gordon S, Lehr C (2018)
ACS infectious diseases 4 (8): 1188-1196DOI: 10.1021/acsinfecdis.7b00165
2017
Bacterial RNAP Inhibitors: Synthesis and Evaluation of Prodrugs of Aryl‐ureidothiophene‐carboxylic acids
Ruthenbeck A, Elgaher W, Haupenthal J, Hartmann R, Meier C (2017)
ChemistrySelect 2 (35): 11899-11905DOI: 10.1002/slct.201702574
2016
Evolution of novel antibiotic Scaffolds targeting the nucleic acid machineries RNA polymerase, DNA gyrase, and topoisomerase IV
Elgaher W (2016)
ThesisDOI: 10.22028/D291-23193
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors
Elgaher W, Sharma K, Haupenthal J, Saladini F, Pires M, Real E, Mely Y, Hartmann R (2016)
Journal of medicinal chemistryDOI: 10.1021/acs.jmedchem.6b00730
2015
Synthesis and biological evaluation of cystobactamid 507: a bacterial topoisomerase inhibitor from Cystobacter sp
Moreno M, Elgaher W, Herrmann J, Schläger N, Hamed M, Baumann S, Müller R, Hartmann R, Kirschning A (2015)
Synlett 26 (9): 1175-1178DOI: 10.1055/s-0034-1380509
2014
Surface plasmon resonance--more than a screening technology: insights in the binding mode of σ70:core RNAP inhibitors
Hüsecken K, Hinsberger S, Elgaher W, Haupenthal J, Hartmann R (2014)
Future medicinal chemistry 6 (14): 1551-65DOI: 10.4155/fmc.14.105
2013
Expanding the scaffold for bacterial RNA polymerase inhibitors: design, synthesis and structure–activity relationships of ureido-heterocyclic-carboxylic acids
Elgaher W, Fruth M, Groh M, Haupenthal J, Hartmann R (2013)
RSC Adv 4 (5): 2177-2194DOI: 10.1039/C3RA45820B
2011
New Theophylline Derivatives
Elgaher W (2011)
Book
Design and synthesis of some new theophylline derivatives with bronchodilator and antibacterial activities
Hayallah A, Elgaher W, Salem O, Alim A (2011)
Arch Pharm Res 34 (1): 3-21DOI: 10.1007/s12272-011-0101-8
2009
SYNTHESIS, ANTI-BRONCHOCONSTRICTIVE, AND ANTIBACTERIAL ACTIVITIES OF SOME NEW 8- SUBSTITUTED-1,3-DIMETHYLXANTHINE DERIVATIVES
Elgaher W, Hayallah A, Salem O, Abdel Alim A (2009)
Bulletin of Pharmaceutical Sciences. Assiut 32 (1): 153-187DOI: 10.21608/BFSA.2009.63355